GM 60106
Alternative Names: GM-60106Latest Information Update: 12 Aug 2024
At a glance
- Originator JD BIOSCIENCE
- Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Small molecules
- Mechanism of Action Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Non-alcoholic steatohepatitis
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
Most Recent Events
- 05 Jun 2024 Pharmacokinetics and adverse events data from a phase I trial in Non-alcoholic steatohepatitis presented at the European Association for the Study of the Liver Congress (EASL-2024)
- 12 Aug 2022 Australian regulatory body approves IND application for GM 60106 in Non-alcoholic steatohepatitis
- 12 Aug 2022 JD BIOSCIENCE files an IND application with the regulatory body in Australia for Non-alcoholic steatohepatitis prior to August 2022